Feature | March 19, 2013

Survival of Sapien High-Risk Patients Equivalent to Surgery at Three Years

Late-breaking data at ACC 2013 further support Sapien as alternative to surgery

Edwards Sapien, PARTNER, 3 year followup

March 19, 2013 — The three-year results of a pivotal clinical study comparing the Edwards Sapien transcatheter heart valve and open-heart surgery demonstrated comparable outcomes. These new data from The PARTNER Trial were presented today as a late-breaking clinical trial at the American College of Cardiology's (ACC) 62nd Annual Scientific Session in San Francisco.

"These three-year data from The PARTNER Trial strengthen the evidence that the Sapien valve is a safe and less-invasive alternative for those patients who need valve replacement, but are at high surgical risk," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves. "The availability of the Sapien valve encourages the many untreated patients to work with a Heart Team to determine whether transcatheter valve replacement or surgery is the right option for them."

At three years, all-cause mortality for patients treated with the Edwards Sapien transcatheter aortic valve replacement (TAVR) delivered via the femoral artery or a small incision between the ribs was statistically equivalent to that of patients who had received open-heart surgical aortic valve replacement (AVR). Symptom improvement and valve performance was similar in both groups and was maintained through the three years of patient follow-up. The incidence of stroke between TAVR and surgery patients was also comparable. (See table below for specific data points.)

The PARTNER Trial is the first randomized, controlled trial of a transcatheter aortic valve in the United States. The high-risk surgery cohort (Cohort A) of the trial enrolled between May 2007 and Sept. 2009 and studied 699 patients with severe, symptomatic aortic stenosis deemed at high risk for traditional open-heart surgery. Patients were evaluated by a multi-disciplinary Heart Team and randomized to receive either traditional open-heart surgery or the Sapien valve with transfemoral or transapical delivery.

The Food and Drug Administration (FDA) approved the Sapien valve in November 2011 for the treatment of inoperable patients, and expanded the indication to high-risk surgical patients in October 2012.

The PARTNER Trial, High-Risk Surgical Cohort (Cohort A)(i)

               1-year                 2-year                 3-year        
          Sapien/Surgery value    Sapien/Surgery value    Sapient/Surgery value 
mortality     24.3 / 26.8  0.45               33.9 / 35.0  0.78                    44.2 / 44.8 0.483 
Stroke:        6 / 3.2  0.08                      7.7 / 4.9  0.17                        8.2 / 9.3 0.763

Note: These data refer to the intention-to-treat (ITT) population.

For more information: edwards.com

Related Content

St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study
News | EP Lab| October 10, 2016
October 10, 2016 — ZipLine Medical Inc.
Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano
News | Heart Valve Technology| October 10, 2016
Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and...
Mercator MedSystems, Bullfrog Micro-Infusion Device, DANCE trial, VIVA 2016, 13-month results
News | Peripheral Arterial Disease (PAD)| October 07, 2016
Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking...
Northwestern Medicine, Edwards Lifesciences, Intuity Elite suturless aortic valve, first in Illinois

Edwards Intuity valve image courtesy of Northwestern Medicine

News | Heart Valve Technology| October 07, 2016
October 7, 2016 — A Northwestern Medicine cardiac surgeon was recently the first in Illinois and second in the United
Overlay Init